Shaanxi Key Laboratory of Brain Disorders & Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, P.R. China.
Institute of Neurobiology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, P.R. China.
J Alzheimers Dis. 2019;67(4):1109-1122. doi: 10.3233/JAD-181084.
Alzheimer's disease (AD) is the most common cause of dementia and is characterized by the progressive loss of memory and cognition in the aging population. However, the etiology of and therapies for AD remain far from understood. Astrocytes, the most abundant neuroglia in the brain, have recently aroused substantial concern due to their involvement in synaptotoxicity, amyloidosis, neuroinflammation, and oxidative stress. In this review, we summarize the candidate molecules of astrocytes, especially receptors and transporters, that may be involved in AD pathogenesis. These molecules include excitatory amino acid transporters (EAATs), metabotropic glutamate receptor 5 (mGluR5), the adenosine 2A receptor (A2AR), the α7-nicotinic acetylcholine receptor (α7-nAChR), the calcium-sensing receptor (CaSR), S100β, and cannabinoid receptors. We describe the characteristics of these molecules and the neurological and pharmacological underpinnings of these molecules in AD. Among these molecules, EAATs, A2AR, and mGluR5 are strongly related to glutamate-mediated synaptotoxicity and are involved in glutamate transmission or the clearance of extrasynaptic glutamate in the AD brain. The α7-nAChR, CaSR, and mGluR5 are receptors of Aβ and can induce a plethora of toxic effects, such as the production of excess Aβ, synaptotoxicity, and NO production triggered by changes in intracellular calcium signaling. Antagonists or positive allosteric modulators of these receptors can repair cognitive ability and modify neurobiological changes. Moreover, blocking S100β or activating cannabinoid receptors reduces neuroinflammation, oxidative stress, and reactive astrogliosis. Thus, targeting these molecules might provide alternative approaches for treating AD.
阿尔茨海默病(AD)是痴呆症最常见的病因,其特征是老年人群中记忆和认知的进行性丧失。然而,AD 的病因和治疗方法仍远未被理解。星形胶质细胞是大脑中最丰富的神经胶质细胞,由于其参与突触毒性、淀粉样变性、神经炎症和氧化应激,最近引起了广泛关注。在这篇综述中,我们总结了星形胶质细胞中可能参与 AD 发病机制的候选分子,特别是受体和转运体。这些分子包括兴奋性氨基酸转运体(EAATs)、代谢型谷氨酸受体 5(mGluR5)、腺苷 A2A 受体(A2AR)、α7-烟碱型乙酰胆碱受体(α7-nAChR)、钙敏感受体(CaSR)、S100β 和大麻素受体。我们描述了这些分子的特征以及这些分子在 AD 中的神经和药理学基础。在这些分子中,EAATs、A2AR 和 mGluR5 与谷氨酸介导的突触毒性密切相关,参与 AD 脑中谷氨酸的传递或突触外谷氨酸的清除。α7-nAChR、CaSR 和 mGluR5 是 Aβ 的受体,可引发多种毒性作用,如产生过量的 Aβ、突触毒性以及细胞内钙信号变化引发的 NO 产生。这些受体的拮抗剂或正变构调节剂可以修复认知能力并改变神经生物学变化。此外,阻断 S100β 或激活大麻素受体可减少神经炎症、氧化应激和反应性星形胶质细胞增生。因此,针对这些分子可能为治疗 AD 提供替代方法。